Several high-dose therapy regimens are used for autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed and refractory Hodgkin's lymphoma (HL) with variable disease response. An intensified regimen of etoposide (VP-16) 2400 mg/m 2 , cyclophosphamide 7200 mg/m 2 and carmustine (BCNU) 600 mg/ m 2 (VCB) pre-auto-HSCT was developed to overcome disease recurrence. A total of 43 relapsed and refractory HL patients underwent auto-HSCT between January 1992 and December 2004. At day 100 there were 37 (86%) complete responses. A total of 40 patients survived beyond day 100, 14 of whom subsequently relapsed/ progressed. At a median follow-up of 4.9 years (range 1.5-11.4 years), 26 patients (60%) are alive and disease free. Five-year actuarial event-free survival (EFS) was 53% (95% CI 35-70%) and median EFS was 5.9 years. Median progression-free and overall survivals have not been reached. EFS was reduced with an increasing number of prognostic factors (Karnofsky performance status, KPS o90, chemotherapy-resistant disease and X3 chemotherapy regimens prior to transplant p1 vs X2; P ¼ 0.049). Grade III-IV regimen-related toxicity was 9% (n ¼ 4). The 1-year cumulative incidence of interstitial pneumonitis (IP) was 36%, however only two patients died of IP complications. Disease progression was the most common cause of death (n ¼ 10, 23%). Intensive VCB is an effective and well-tolerated preparative regimen for relapsed and refractory HL auto-HSCT.
Introduction
Relapsed and refractory Hodgkin's lymphoma (HL) patients have a poor prognosis with low-dose salvage chemotherapy, yielding a cure rate of 20% or less. [1] [2] [3] [4] Highdose therapy followed by autologous blood or marrow transplantation (autologous hematopoietic stem cell transplantation, auto-HSCT) has become a standard treatment for patients refractory to or relapsing after induction therapy [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] as low-dose salvage therapy alone is usually ineffective. 18 Transplant-related prognostic factors such as chemotherapy sensitivity, disease status at auto-HSCT, Karnofsky performance status (KPS) at the time of transplant, number of pre-transplant chemotherapy regimens and extranodal disease have been reported to predict which patients are likely to benefit most from auto-HSCT. 8, [19] [20] [21] [22] [23] However, disease recurrence post transplant remains the single major cause of treatment failure. 24 Classical cyclophosphamide, carmustine (BCNU) and etoposide (CBV) combination is a standard conditioning regimen prior to auto-HSCT for patients with HL. Many modifications of the CBV regimen have been employed with varying results. 8, 19, [21] [22] [23] [24] [25] [26] [27] [28] In an attempt to decrease recurrence rates, more intense conditioning regimens have yielded better responses albeit at the cost of increased toxicity. 21, 23, 25 We report our single-institution experience of an intensified VCB conditioning regimen with a unique dosing schedule of infusional etoposide, bolus cyclophosphamide and higher dose BCNU sequentially followed by auto-HSCT in the treatment of relapsed or refractory HL.
Patients and methods

Patients
A total of 43 patients with relapsed or refractory HL underwent auto-HSCT at Roswell Park Cancer Institute (RPCI) between January 1992 and December 2004. Patient characteristics are summarized in Table 1 . All patients were treated on a single clinical protocol with standard eligibility criteria including age 45 and p70, adequate cardiac, pulmonary, hepatic and renal function and KPS X70. After 1998, patients above the age of 60 were not treated with this regimen. Eighteen HL patients were treated with other conditioning regimens from 1992 to 1997 and are not part of this analysis. All patients signed informed consent for a protocol approved by the Institutional Review Board at RPCI and were followed prospectively. All data have been de-identified.
In an attempt to achieve maximum cytoreduction, 40 of 43 patients received salvage therapy with conventional platinum-based chemotherapy regimens (n ¼ 35) or radiation therapy (mantle, n ¼ 4 and inverted Y, n ¼ 1) prior to auto-HSCT. Three patients underwent auto-HSCT in early relapse with no salvage chemotherapy.
Patients who achieved a complete or partial response to salvage therapy were categorized as chemotherapy sensitive (n ¼ 26). Those who underwent auto-HSCT directly without salvage therapy (n ¼ 3) and those who received salvage therapy but were not evaluated for disease response prior to transplant (n ¼ 1) were categorized as not evaluated (NE, n ¼ 4). All others were defined as having chemotherapy-resistant disease (n ¼ 13).
Disease progression post transplantation was defined as evidence of relapse in patients with a documented CR after auto-HSCT, evidence of new areas of disease post-auto-HSCT, evidence of tumor growth in areas of persistent disease post-auto-HSCT or death due to disease. Bearman criteria were used to assess regimen-related toxicities (RRT) up to day þ 100 in eight organ systems including cardiac, renal, bladder, pulmonary, hepatic, gastrointestinal, mucosal and central nervous system. 29 
Transplantation
The conditioning regimen was a combination of etoposide (VP-16) 2400 mg/m 2 34 h continuous intravenous infusion starting on day À8, cyclophosphamide 1800 mg/m 2 over 2 h daily on days À7, À6, À5 and À4, and BCNU 600 mg/m 2 over 2 h on day À3 (Figure 1) . 24, 26 Stem cells were reinfused on day 0. Stem cell source was PBSC (n ¼ 32), BM (n ¼ 3) or both PBSC and BM (n ¼ 8). All patients received standard transplant supportive care and antimicrobial prophylaxis with fluconazole and acyclovir.
Hematopoietic recovery
Successful engraftment of infused stem cells was defined as an ANC X500/mm 3 for 3 consecutive days and a platelet count of X20 000/mm 3 after 7 consecutive days with no platelet transfusions. Granulocyte or granulocyte-macrophage CSF was administered starting on day þ 5 until neutrophil engraftment was achieved. Failure to engraft was defined as survival to day þ 42 without ANC recovery.
Statistical analysis
The primary outcome analyzed was event-free survival (EFS) after transplant. Progression-free survival (PFS), overall survival (OS) and RRT were analyzed as secondary end points. The w 2 -test (with Fisher's exact test, where applicable) was used to compare proportions. Tests of significance were two sided with Po0.05 considered statistically significant. All analyses were conducted using the intent-to-treat principle. Kaplan-Meier survival curves b Three patients in first complete remission with radiographic abnormalities of unknown significance (CRu1) at time of auto-HSCT, had 2-3 chemotherapy regimens to achieve CR1 and were treated as high-risk refractory patients.
VCB and auto-HSCT for Hodgkin's lymphoma M Benekli et al were calculated from the date of hematopoietic stem cell infusion (day 0). 30 Differences in survival between the prognostic factor risk groups were assessed by the logrank test. Survival status for all patients was updated through 31 March 2007. Median follow-up was calculated from day 0 until date of last contact in the surviving patients. All patients are included in the analysis for EFS and were censored only at time of last follow-up if disease progression did not occur; events were disease relapse, progression or death due to any cause. All patients were included in the analysis for PFS and were censored at the time of last follow-up if disease progression did not occur or at death if disease progression did not occur; events were disease relapse or progression. All patients were included in the analysis for OS and were censored at time of last follow-up; events were death due to any cause. The prognostic model of EFS at 2 years used a Cox proportional hazards model with forward stepwise selection conditional on the likelihood ratio with Po0.05 to enter and P40.1 to remove each factor from the model. 30 The Cox proportional hazards model considered the following factors in the multivariate prognostic model as previously published: 19 poor performance status (KPSo90), chemotherapy-resistant disease at transplant and three or more chemotherapy regimens prior to auto-HSCT.
Results
Hematopoietic engraftment
All patients achieved neutrophil engraftment at a median of 12 days (range 9-18 days). No patients failed to engraft neutrophils. Two patients died before achieving platelet recovery on days þ 22 and þ 62. The remaining 41 patients had platelet engraftment a median of 17 days post-auto-HSCT (range 9-46 days).
Response
A total of 37 patients (86%) achieved or maintained a CR by 100 days following auto-HSCT, including one patient who achieved a CR after planned post-auto-HSCT radiation therapy. Three patients had no response/progressive disease. Three patients could not be evaluated because of early death due to transplant-related causes on days þ 22, 57 and 62. Post auto-HSCT planned consolidation radiation therapy was given to eight patients (five mantle/ mediastinum, two neck and one abdomen).
Of the 40 patients who survived beyond day 100, 14 (33%) relapsed/progressed including 11 patients who had attained a CR post-auto-HSCT. Seven of these relapsed patients underwent a subsequent allogeneic (allo) HSCT; three of whom are alive and disease free 129 days, 3.4 and 3.9 years post-allo-HSCT. The remaining seven patients were treated with salvage chemotherapy and/or radiation, and all died of HL.
Survival
Of 43 patients, 40 (93%) survived to day 100. In all, 26 patients (60%) are still alive and disease free at a median follow-up of 4.9 years (range 1.5-11.4 years). Median EFS was 5.9 years and median OS has not yet been reached for all patients (Figure 2) . Five-year actuarial EFS was 53% (95% CI 35-70%), PFS 63% (95% CI 46-80%) and OS 57% (95% CI 41-74%). Overall, the most common cause of death was disease progression (n ¼ 10, 23%); other causes were RRT on day þ 62 (n ¼ 1), RRT after subsequent allo-HSCT (n ¼ 1), postoperative complication on day þ 57 (n ¼ 1), lung disease (interstitial pneumonitis (IP) developing 45 years post-auto-HSCT; n ¼ 1), secondary AML (n ¼ 1), subdural hematoma secondary to a fall on day þ 22 (n ¼ 1) and unknown (n ¼ 1).
Four of the five patients who received only radiation therapy for salvage pre-HSCT are still alive in continuous complete remission 8.5-11 years post-HSCT. The fifth patient died of IP almost 6 years post-HSCT and was in continuous complete remission post-HSCT. The three patients who did not receive salvage chemotherapy or radiation for early relapse prior to HSCT are all alive in continuous complete remission 7-10 years post-HSCT.
In subgroup analyses, duration of first CR and chemosensitivity at HSCT were not significantly associated with OS, EFS or PFS. The nonsignificant results are probably due to a lack of statistical power, since only 12 patients had a first CR412 months, and only 13 had chemo-resistant disease at time of HSCT. Five-year OS was 73% (95% CI 46-100%) for patients with CR1412 months and 50% (95% CI 30-70%) for those with CR1o12 months (P ¼ 0.15). The corresponding numbers for 5-year EFS were 67% (95% CI 40-94%) and 47% (95% CI 27-67%), respectively (P ¼ 0.23). Similarly, 5-year OS in patients with chemosensitive disease at HSCT was 56% (95% CI 35-77%) and 46% (95% CI 10-82%) for those with chemoresistant disease (P ¼ 0.7). The corresponding numbers for 5-year EFS were 55% (95% CI 35-75%) and 54% (95% CI 27-81%), respectively (P ¼ 0.5).
We confirmed that the prognostic model for risk using poor performance status (KPSo90), chemotherapy-resistant disease at transplant, and three or more chemotherapy and overall survival (OS, solid line) post-auto-HSCT in relapse or refractory Hodgkin's disease using VCB conditioning regimen.
VCB and auto-HSCT for Hodgkin's lymphoma M Benekli et al regimens prior to auto-HSCT is valid in this patient population as EFS was statistically different in patients with p1 vs X2 prognostic factors ( Figure 3 ).
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Toxicity Table 2 summarizes the frequency of RRT by organ system through day þ 100. Overall, 32 patients (74%) developed mild to moderate grade I-II RRT, mainly stomatitis (n ¼ 21, 49%). Severe RRT (grade III-IV) was uncommon (n ¼ 5, 12%). IP developed in 33% (grade I-II, n ¼ 11 (26%) and grade III-IV, n ¼ 3 (7%)). The diagnosis of IP was made by computed axial tomography scan and bronchoscopy/transbronchial biopsy/open lung biopsy in selected cases. The 1-year cumulative incidence of IP was 36% after correction for follow-up time and early deaths due to competing causes. Median time to the development of IP was 40 days (range 13-69) with only one patient developing IP more than 5 years post-auto-HSCT. Among patients with IP, two patients (5%) had grade III reversible (on days þ 13 and þ 60) and one (2%) had grade IV fatal IP (on day þ 62). All three patients with grade III-IV IP received prior mediastinal radiation therapy including one who had planned post-auto-HSCT consolidation radiation therapy. Of the 23 patients who received mediastinal radiotherapy before or after auto-HSCT, 11 developed IP (48%) compared to 5 of 20 patients (25%) who did not (P ¼ 0.11). The number of chemotherapy regimens prior to auto-HSCT did not affect development of IP. There were no life-threatening infectious complications. There was no central nervous system toxicity. One patient developed prostate cancer and one patient developed myelodysplastic syndrome progressing to AML with complex cytogenetic abnormalities including monosomy 7 and died þ 50 months post-auto-HSCT of complications during AML therapy.
Discussion
High-dose therapy combined with auto-HSCT is the treatment of choice for patients with HL who have failed to respond or relapse after first-line chemotherapy. However, the conditioning regimen that offers the best outcome with the least toxicity has yet to be defined. Multiple studies of auto-HSCT employing the CBV regimen at varying dose levels have shown that patients with relapsed HL have actuarial survival rates of approximately 50% with failurefree survival rates of 40%. 8, [31] [32] [33] [34] These results are comparable to TBI-based regimens, 8, 20 TLI-based regimens 35, 36 and to those using BEAM (BCNU, etoposide, ara-C, and melphalan). [37] [38] [39] [40] [41] Schedules of the CBV regimen employing a higher dose of infusional etoposide have been used in combination with maximum tolerated doses of cyclophosphamide and BCNU 24, 26 in an attempt to overcome multidrug resistance and decrease mucositis severity. However, RRT has limited these efforts to a large extent as large cumulative doses and prolonged administration of BCNU is associated with increased pulmonary toxicity. CBV, which is the most commonly used high-dose preparatory regimen for HL, has notable increases in IP depending on the dose of BCNU. Although a number of authors have reported pulmonary toxicity with high-dose BCNU (4600 mg/m 2 ), no difference in IP was seen in a nonrandomized study of allograft recipients whether a dose of 300 or 600 mg/m 2 was given. 27, 28, 42, 43 With disease recurrence as the major cause of treatment failure it would be reasonable to accept the reversible pulmonary toxicity of IP, if patient outcomes are improved.
The pharmacokinetics of BCNU is critically affected by drug sequencing as well as dose. The frequency of pulmonary toxicity is fourfold greater with BCNU 600 mg/ m 2 administered after etoposide and cyclophosphamide when compared to BCNU 300 mg/m 2 given on the first day of therapy. 44 The pharmacologic explanation for these proportional differences in AUC and toxicity is unclear. The major metabolic pathway for elimination of BCNU is through cytochrome p-450 reductase, which can be inhibited by alkylation of p-450 protein from cisplatin and cyclophosphamide. 44, 45 Moreover, genetic variability affecting the activity of enzymes that metabolize and detoxify chemotherapeutic drugs and radiation may explain some of the interindividual variability in RRT. Table 2 Regimen-related toxicity In this study, pulmonary toxicity was a major concern with 14 patients (33%) developing IP. Although reversible in most cases, IP was responsible for two deaths. The higher incidence of IP compared to historical literature data may in part be due to the high-dose BCNU used in our study, since doses greater than 450 mg/m 2 have been reported to be associated with higher incidence of IP. 26, 28 However, a detailed description of pulmonary toxicity is lacking in most reports. 24, 26 Therefore, the incidence of grade I-II IP in this study may be high due to underreporting of mild to moderate IP in the literature with more emphasis on severe grade III-IV toxicity. For example, employing a similar VCB schedule, Fleming et al. 26 reported a 5% grade III-IV IP without documenting grade I-II IP. However, the dose of BCNU was decreased to 300 mg/m 2 after the recruitment of half of the study group with a subsequent decrease in pulmonary toxicity. 26 Bolwell et al. 24 focused on predictors of disease relapse following auto-HSCT and did not discuss treatment-related toxicity. Although 33% of the patients in our cohort had IP, most were diagnosed promptly and successfully treated with complete resolution of clinical and radiological findings.
This study demonstrates that intensified VCB has a high response rate (86% CR) with low toxicity and no engraftment failures. The 5-year PFS and OS rates of 62 and 57% are similar to other CBV schedules. 24, 26 Fatal toxicity was uncommon (2%) and continuous infusion etoposide was not associated with severe mucositis. Disease relapse was a prominent cause of treatment failure with a 33% relapse rate, which is comparable to other series. Relapses (12 of 14) were within 2 years after auto-HSCT with median PFS not yet reached. Therefore, the likelihood of cure once the patient is 2-years post-auto-HSCT without relapse is over 90%.
However, due to a shift in strategy, we do not routinely transplant higher risk patients unless there is an alternative plan for continued therapy. Based on our prognostic risk model, we have identified a group of HL patients who have a high risk of relapse even after dose-intensified VCB. 19 Our current approach consists of dose-intensive VCB and auto-HSCT for high-risk patients; patients with residual disease at day þ 100 post-auto-HSCT are offered a reduced intensity conditioning (RIC) allo-HSCT. As part of this approach, identification of a suitable related or unrelated donor is undertaken at the time of auto-HSCT to prepare for early RIC allo-HSCT in this high-risk population.
Intensified VCB is a well-tolerated and highly effective preparative regimen for the treatment of relapsed or refractory HL with a reasonable toxicity profile. Reversible pulmonary toxicity is frequent, warranting close follow-up and prompt intervention.
